Phenotypic evaluation and in silico ADMET properties of novel arylimidamides in acute mouse models of Trypanosoma cruzi infection

References

• World Health Organization [webpage on the Internet]WHO Fact Sheet No 3402015 Available from: http://www.who.int/mediacentre/factsheets/fs340/en/Accessed November 3, 2016
   Google Scholar
• BarrettMPCroftSLManagement of trypanosomiasis and leishmaniasisBr Med Bull2012104 175 19623137768
   PubMed Web of Science ®Google Scholar
• Drugs for Neglected Disease initiative (DNDi, 2016) [webpage on the Internet]Paediatric dosage form of benznidazole (Chagas) Available from: http://www.dndi.org/diseases-projects/portfolio/benznidazole-paedriatric-dosage-form.htmlAccessed November 3, 2016
   Google Scholar
• HotezPJDumonteilEWoc-ColburnLChagas disease: “the new HIV/AIDS of the Americas”PLoS Negl Trop Dis20126 e149822666504
   PubMed Web of Science ®Google Scholar
• ChatelainEChagas disease drug discovery: toward a new eraJ Biomol Screen2015201 22 3525245987
   PubMedGoogle Scholar
• TestonAPMonteiroWMReisDIn vivo susceptibility to benznidazole of Trypanosoma cruzi strains from the western Brazilian AmazonTrop Med Int Health2013181 85 9523130989
   PubMed Web of Science ®Google Scholar
• ZingalesBAraujoRGMorenoMA novel ABCG-like transporter of Trypanosoma cruzi is involved in natural resistance to benznidazoleMem Inst Oswaldo Cruz20151103 433 44425946152
   PubMed Web of Science ®Google Scholar
• SoeiroMNDantasAPDaliryAExperimental chemotherapy for Chagas disease: 15 years of research contributions from in vivo and in vitro studiesMem Inst Oswaldo Cruz2009104suppl 1 301 31019753489
   PubMed Web of Science ®Google Scholar
• AptWCurrent and developing therapeutic agents in the treatment of Chagas diseaseDrug Des Devel Ther201024 243 253
   Web of Science ®Google Scholar
• MayaJDOrellanaMFerreiraJKemmerlingULópez-MuñozRMorelloAChagas disease: present status of pathogenic mechanisms and chemotherapyBiol Res2010433 323 33121249304
   PubMed Web of Science ®Google Scholar
• DíazMVMirandaMRCampos-EstradaCPentamidine exerts in vitro and in vivo anti Trypanosoma cruzi activity and inhibits the polyamine transport in Trypanosoma cruziActa Trop2014134 1 924560964
   PubMed Web of Science ®Google Scholar
• SoeiroMNWerbovetzKBoykinDWWilsonWDWangMZHemphillANovel amidines and analogues as promising agents against intracellular parasites: a systematic reviewParasitology20131408 929 95123561006
   PubMed Web of Science ®Google Scholar
• SilvaCFBatistaMMMotaRAActivity of “reversed” diamidines against Trypanosoma cruzi in vitroBiochem Pharmacol200773 1939 194617462605
   PubMed Web of Science ®Google Scholar
• SilvaCFMeuserMBDe SouzaEMCellular effects of reversed amidines on Trypanosoma cruziAntimicrob Agents Chemother20075111 3803 380917698624
   PubMed Web of Science ®Google Scholar
• RosypalACWerbovetzKASalemMInhibition by Dications of in vitro growth of Leishmania major and Leishmania tropica: causative agents of old world cutaneous leishmaniasisJ Parasitol2008943 743 74918605790
   PubMed Web of Science ®Google Scholar
• TimmBLda SilvaPBBatistaMMIn vitro and in vivo biological effects of novel arylimidamide derivatives against Trypanosoma cruziAntimicrob Agents Chemother2014587 3720 372624752263
   PubMed Web of Science ®Google Scholar
• Da SilvaCFBatistaMMBatistaDGIn vitro and in vivo studies of the trypanocidal activity of a diarylthiophene diamidine against Trypanosoma cruziAntimicrob Agents Chemother2008529 3307 331418625779
   PubMed Web of Science ®Google Scholar
• BatistaDGBatistaMMde OliveiraGMArylimidamide DB766, a potential chemotherapeutic candidate for Chagas’ disease treatmentAntimicrob Agents Chemother2010547 2940 295220457822
   PubMed Web of Science ®Google Scholar
• De AraújoJSDa SilvaCFBatistaDGIn vitro and in vivo studies of the biological activity of novel arylimidamides against Trypanosoma cruziAntimicrob Agents Chemother2014587 4191 419524590476
   PubMed Web of Science ®Google Scholar
• Da SilvaCFBatistaDGOliveiraGMIn vitro and in vivo investigation of the efficacy of arylimidamide DB1831 and its mesylated salt form – DB1965 – against Trypanosoma cruzi infectionPLoS One201271 e3035622291940
   PubMed Web of Science ®Google Scholar
• Guedes-da-SilvaFHBatistaDGMeuserMBIn vitro and in vivo trypanosomicidal action of novel arylimidamides against Trypanosoma cruziAntimicrob Agents Chemother201660suppl 4 2425 243426856830
   PubMed Web of Science ®Google Scholar
• Da SilvaCFDaliryASilvaPBThe efficacy of arylimidamides against Trypanosoma cruzi in vitroParasitology2011138 1863 186921902869
   PubMed Web of Science ®Google Scholar
• StephensCEBrunRSalemMMThe activity of diguanidino and ‘reversed’ diamidino 2,5-diarylfurans versus Trypanosoma cruzi and Leishmania donovaniBioorg Med Chem Lett20031312 2065 206912781196
   PubMed Web of Science ®Google Scholar
• WangMZZhuXSrivastavaANovel arylimidamides for treatment of visceral LeishmaniasisAntimicrob Agents Chemother201054 2507 251620368397
   PubMed Web of Science ®Google Scholar
• ChaiYMundeMKumarAStructure-dependent binding of arylimidamides to the DNA minor grooveChembiochem2014151 68 7924323836
   PubMed Web of Science ®Google Scholar
• MeirellesMNde Araujo-JorgeTCMirandaCFde SouzaWBarbosaHSInteraction of Trypanosoma cruzi with heart muscle cells: ultrastructural and cytochemical analysis of endocytic vacuole formation and effect upon myogenesis in vitroEur J Cell Biol1986412 198 2063093234
   PubMed Web of Science ®Google Scholar
• PiresDEBlundellTLAscherDBpkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signaturesJ Med Chem2015589 4066 407225860834
   PubMed Web of Science ®Google Scholar
• Roman-CamposDSales-JúniorPDuarteHLCardiomyocyte dysfunction during the chronic phase of Chagas diseaseMem Inst Oswaldo Cruz20131082 243 24523579807
   PubMed Web of Science ®Google Scholar
• SoeiroMNde CastroSLScreening of potential anti-Trypanosoma cruzi candidates: in vitro and in vivo studiesOpen Med Chem J20115 21 3021629508
   PubMedGoogle Scholar
• Marin-NetoJARassiAJrAvezumAJrBENEFIT InvestigatorsThe BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart diseaseMem Inst Oswaldo Cruz2009104suppl 1 319 32419753491
   PubMed Web of Science ®Google Scholar
• MorilloCAMarin-NetoJAAvezumARandomized trial of benznidazole for chronic Chagas’ cardiomyopathyN Engl J Med2015373 1295 130626323937
   PubMed Web of Science ®Google Scholar
• MaguireJHTreatment of Chagas’ disease – time is running outN Engl J Med2015373 1369 137026323936
   PubMed Web of Science ®Google Scholar
• CummingJGDavisAMMuresanSHaeberleinMChenHChemical predictive modelling to improve compound qualityNat Rev Drug Discov20131212 948 96224287782
   PubMed Web of Science ®Google Scholar
• LiFLuJMaXCPY3A4-mediated lopinavir bioactivation and its inhibition by ritonavirDrug Metab Dispos201240 18 2421953914
   PubMed Web of Science ®Google Scholar
• GutmanGAChandyKGGrissmerSInternational Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channelsPharmacol Rev200557suppl 4 473 50816382104
   PubMed Web of Science ®Google Scholar
• MolinaIGómezIPratJRandomized trial of posaconazole and benznidazole for chronic Chagas’ diseaseN Engl J Med2014370 1899 190824827034
   PubMed Web of Science ®Google Scholar
• PattersonSWyllieSNitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospectsTrends Parasitol2014306 289 29824776300
   PubMed Web of Science ®Google Scholar